Search and analyze individual stocks with comprehensive metrics
Piramal Pharma Ltd
Fundamental Score
Piramal Pharma Ltd Share Price Live NSE/BSE
Profitability Metrics
Return on Equity
Return on Capital Employed
Operating Profit Margin (5Y)
Dividend Yield
Valuation Metrics
Price to Earnings
Market Capitalization
Industry P/E
Growth Metrics
YoY Quarterly Profit Growth
YoY Quarterly Sales Growth
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Financial Health
Debt to Equity
Interest Coverage
Free Cash Flow (5Y)
Ownership Structure
Promoter Holding
FII Holding
DII Holding
Pledged Percentage
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Market Data Analysis & Educational Insights
Educational evaluation of PPLPHARMA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Operating Margins (15.15%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages. This indicates sustainable profitability potential.
Strong Institutional Confidence (FII+DII: 45.16%)
Observation: Significant professional investor participation indicates quality recognition.
Analysis: High institutional holding often signals thorough due diligence and quality business fundamentals.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral, reducing forced-selling risk.
Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.
Risk Factors
7 factors identified
Below-Average Return on Equity (1.11%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (6.45%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation. Review business model and competitive positioning.
Profit Decline Concern (-539.22%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes. Monitor for recovery signs and management guidance.
Revenue Contraction (-8.83%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions and competitive positioning. Monitor recovery strategies.
Weak Interest Coverage (1.52x)
Observation: Limited ability to service debt obligations from earnings.
Analysis: Low interest coverage raises concerns about financial stability. Monitor cash flow and debt reduction plans.
Negative Free Cash Flow (₹-29.18 Cr over 5Y)
Observation: Cash outflows exceed inflows, indicating capital intensity or working capital issues.
Analysis: Negative FCF requires analysis of capital expenditure cycle and working capital management efficiency.
Very Low ROE
Observation: Poor capital utilization and shareholder returns.
Analysis: ROE below 5% suggests significant inefficiencies in capital deployment.
Loading Peer Comparison
Finding companies in the Pharmaceuticals sector...
Financial Statements
Comprehensive financial data for Piramal Pharma Ltd
About PPLPHARMA
Business Overview
Piramal Pharma Limited operates as a pharmaceutical company in the United States, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; offers inhalation anesthetics, intrathecal therapy, injectable pain and anesthesia drugs, and other generic and specialty products; and analgesics, skin care, vitamin/mineral supplement, kids' wellness, digestives, women's health, and hygiene, as well as adult incontinence. The company was incorporated in 2020 and is based in Mumbai, India.
Company Details
Key Leadership
Corporate Events
PPLPHARMA Stock Details & Analysis
Key Financial Metrics
Growth & Valuation
Frequently Asked Questions
What is the current price of Piramal Pharma Ltd (PPLPHARMA)?
As of 16 Jan 2026, 10:15 am IST, Piramal Pharma Ltd (PPLPHARMA) is currently trading at ₹166.28. The stock has a market capitalization of ₹24.56K (Cr).
Is PPLPHARMA share price Overvalued or Undervalued?
PPLPHARMA is currently trading at a P/E ratio of 0.00x, compared to the industry average of 31.77x. Based on this relative valuation, the stock appears to be Fairly Valued against its sector peers.
What factors affect the Piramal Pharma Ltd share price?
Key factors influencing PPLPHARMA's price include its quarterly earnings growth (Sales Growth: -8.83%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Piramal Pharma Ltd a good stock for long-term investment?
Piramal Pharma Ltd shows a 5-year Profit Growth of N/A% and an ROE of 1.11%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.60 before investing.
How does Piramal Pharma Ltd compare with its industry peers?
Piramal Pharma Ltd competes with major peers in the Pharmaceuticals. Investors should compare PPLPHARMA's P/E of 0.00x and ROE of 1.11% against the industry averages to determine its competitive standing.
What is the P/E ratio of PPLPHARMA and what does it mean?
PPLPHARMA has a P/E ratio of N/Ax compared to the industry average of 31.77x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹N/A for every ₹1 of annual earnings.
How is PPLPHARMA performing according to Bull Run's analysis?
PPLPHARMA has a Bull Run fundamental score of 2.3/100, which indicates concerns that require careful analysis. This comprehensive rating is based on 15+ financial parameters including profitability, growth metrics, and valuation ratios.
What sector and industry does PPLPHARMA belong to?
PPLPHARMA operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Piramal Pharma Ltd.
What is Return on Equity (ROE) and why is it important for PPLPHARMA?
PPLPHARMA has an ROE of 1.11%, which suggests challenges in generating returns from shareholders' equity. Return on Equity measures how efficiently Piramal Pharma Ltd generates profits from shareholders' equity.
How is PPLPHARMA's debt-to-equity ratio and what does it indicate?
PPLPHARMA has a debt-to-equity ratio of 0.60, which indicates moderate leverage that should be monitored. A ratio below 1.0 generally indicates conservative financing.
What is PPLPHARMA's dividend yield and is it a good dividend stock?
PPLPHARMA offers a dividend yield of 0.08%, which means you receive ₹0.08 annual dividend for every ₹100 invested.
How has PPLPHARMA grown over the past 5 years?
PPLPHARMA has achieved 5-year growth rates of: Sales Growth N/A%, Profit Growth N/A%, and EPS Growth N/A%.
What is the promoter holding in PPLPHARMA and why does it matter?
Promoters hold 34.86% of PPLPHARMA shares, with 0.00% of promoter shares pledged. High promoter holding often indicates strong management confidence.
What is PPLPHARMA's market capitalization category?
PPLPHARMA has a market capitalization of ₹24555 crores, placing it in the Large-cap category.
How volatile is PPLPHARMA stock?
PPLPHARMA has a beta of N/A. A beta > 1 suggests the stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is the 52-week high and low for PPLPHARMA?
PPLPHARMA has a 52-week high of ₹N/A and low of ₹N/A.
What is PPLPHARMA's operating profit margin trend?
PPLPHARMA has a 5-year average Operating Profit Margin (OPM) of 15.15%, indicating the company's operational efficiency.
How is PPLPHARMA's quarterly performance?
Recent quarterly performance shows YoY Sales Growth of -8.83% and YoY Profit Growth of -539.22%.
What is the institutional holding pattern in PPLPHARMA?
PPLPHARMA has FII holding of 30.27% and DII holding of 14.89%. Significant institutional holding often suggests professional confidence in the stock.